TY - JOUR
T1 - The effect of SARS-CoV-2 mRNA vaccination on AMH concentrations in infertile women
AU - Horowitz, Eran
AU - Mizrachi, Yossi
AU - Ganer Herman, Hadas
AU - Oz Marcuschamer, Einat
AU - Shalev, Amir
AU - Farhi, Jacob
AU - Barber, Elad
AU - Orna, Schwartz Harari
AU - Raziel, Arieh
AU - Weissman, Ariel
N1 - Publisher Copyright:
© 2022 Reproductive Healthcare Ltd.
PY - 2022/10
Y1 - 2022/10
N2 - Research question: Does SARS-CoV-2 mRNA vaccination affect the ovarian reserve of infertile women undergoing IVF? Design: This was a prospective observational study at a single university-affiliated IVF unit that included infertile women aged 18–44 years who were undergoing IVF/intracytoplasmic sperm injection between November 2020 and September 2021, had received two doses of SARS-CoV-2 mRNA vaccination and had undergone measurement of baseline anti-Müllerian hormone (AMH) concentration within the 12 months preceding their recruitment. AMH concentrations before and after vaccination were evaluated and compared. Results: Overall, 31 women were included in the study. The median AMH concentrations before and after COVID-19 vaccine were comparable (1.7 versus 1.6 g/ml, respectively, P = 0.96). No correlation was found between the participant's anti-COVID-19 antibody titre and the change in AMH concentration. Conclusions: SARS-CoV-2 mRNA vaccination does not adversely affect ovarian reserve, as shown by comparing serum AMH concentrations before and after vaccination. These findings may serve as a counselling tool for clinicians to reassure women undergoing fertility treatment that SARS-CoV-2 mRNA vaccination is safe.
AB - Research question: Does SARS-CoV-2 mRNA vaccination affect the ovarian reserve of infertile women undergoing IVF? Design: This was a prospective observational study at a single university-affiliated IVF unit that included infertile women aged 18–44 years who were undergoing IVF/intracytoplasmic sperm injection between November 2020 and September 2021, had received two doses of SARS-CoV-2 mRNA vaccination and had undergone measurement of baseline anti-Müllerian hormone (AMH) concentration within the 12 months preceding their recruitment. AMH concentrations before and after vaccination were evaluated and compared. Results: Overall, 31 women were included in the study. The median AMH concentrations before and after COVID-19 vaccine were comparable (1.7 versus 1.6 g/ml, respectively, P = 0.96). No correlation was found between the participant's anti-COVID-19 antibody titre and the change in AMH concentration. Conclusions: SARS-CoV-2 mRNA vaccination does not adversely affect ovarian reserve, as shown by comparing serum AMH concentrations before and after vaccination. These findings may serve as a counselling tool for clinicians to reassure women undergoing fertility treatment that SARS-CoV-2 mRNA vaccination is safe.
KW - Anti-Müllerian hormone
KW - COVID-19
KW - Fertility
KW - Ovarian reserve
KW - SARS-CoV-2 mRNA vaccine
UR - http://www.scopus.com/inward/record.url?scp=85136111909&partnerID=8YFLogxK
U2 - 10.1016/j.rbmo.2022.06.015
DO - 10.1016/j.rbmo.2022.06.015
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 35985956
AN - SCOPUS:85136111909
SN - 1472-6483
VL - 45
SP - 779
EP - 784
JO - Reproductive BioMedicine Online
JF - Reproductive BioMedicine Online
IS - 4
ER -
